# Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Source: https://onco.cc/trials/nct07242274/  
OnCo record `nct07242274` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of docetaxel in lung cancer, run by Jemincare, not yet recruiting.

## Summary

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC is a phase 3, randomised interventional study registered as NCT07242274 by Jemincare, with a registry enrolment figure of 472 participants, started 2025-12-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: JMKX001899; Docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer). Primary outcome: PFS. Lung eligibility wording from the registry: "Histologically or cytologically confirmed NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07242274
- Phase: 3
- Setting: A Multicenter, Randomized, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of JMKX001899 Versus Docetaxel in Previously Treated Patients With KRAS G12C-Mutant Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Jemincare
- Enrolled: 472

## Sources

- ClinicalTrials.gov NCT07242274: https://clinicaltrials.gov/study/NCT07242274

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07242274.json